Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
173 Leser
Artikel bewerten:
(0)

The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data

Finanznachrichten News

-- Launches with rare disease researchers from major research institutions on four continents; Exchange to host the 10,000 exomes of the Simons Simplex Collection to speed autism research

CAMBRIDGE, Massachusetts, Oct. 19, 2014 /PRNewswire/ -- NextCODE Health, which enables clinicians and researchers to use full power of the whole genome in real time, today announced the launch of its new genomic data analysis and collaboration service, the NextCODE Exchange, at the American Society of Human Genetics (ASHG) annual meeting in San Diego. To learn more, sign up and apply for free beta access, visit www.nextcode.com. A brief video on its unique features and benefits can be viewed here.

Logo - http://photos.prnewswire.com/prnh/20140922/147714LOGO
Logo - http://photos.prnewswire.com/prnh/20141019/152964LOGO
Video - http://origin-qps.onstreammedia.com/origin/multivu_archive/PRNA/FX-NE41464-20141019-1.mp4

The Exchange:

  • Lets clinicians and scientists collaborate seamlessly using massive sequence data, and to validate findings with colleagues and institutions around the world - at raw read resolution, in real time, from any browser.
  • Brings together NextCODE's unique database architecture and proven sequence analysis system, optimized on the world's largest collection of whole-genome variant data.
  • Enables users to rapidly visualize their own aligned raw sequence and that of collaborators, access harmonized and updated public reference data, and leave big raw data files right where they reside.
  • Data-sharing settings can be adjusted for every case, project or institution, for full compliance with user rules and consents.

"The genomics community is now generating the sequence data to solve more rare disease cases and find high-impact variants in complex traits. The ability to visually confirm findings in raw sequence at a click, and to validate findings by securely sharing data with other researchers working on the same diseases elsewhere, will help to crack more difficult diagnostic cases and speed discovery. We have a fantastic group of launch partners, global leaders in rare disease and autism research, who will be able to use and demonstrate the Exchange's scalability and reach," said Jeffrey Gulcher, MD, PhD, President and CSO of NextCODE.

"The ability to work with internal and external colleagues through one platform in this way marks a qualitative advance for the field. The goal of sequence-based diagnostics is to pinpoint the cause of more diseases. Instant online access to both sequence and reference data will help us achieve that and do it much more swiftly for patients here and abroad," said Dr Sean Ennis, director at the Academic Centre on Rare Diseases (ACoRD) at University College Dublin and an Exchange launch partner.

Exchange sharing options include no sharing, for privately using the exchange tools and harmonized public data; full sample sharing, to make current collaborations seamless and more productive; blind, aggregate sharing to validate findings in specific phenotypes and identify controls within the Exchange; and approved portal access, through which organizations using the Exchange to host their collections can grant access to approved researchers.

Launch partners include clinicians and researchers affiliated with Boston Children's Hospital, University College Dublin, Queensland Institute of Medical Research (Australia) and Saitama Medical University (Japan). Those at dozens of institutions worldwide using NextCODE's solutions and database infrastructure are also immediately able to take their studies and collaborations into the Exchange.

NextCODE puts the world's most proven sequence analysis platform in the hands of clinicians and researchers around the globe, enabling them to use the full power of NGS data to better diagnose and treat disease. Our solutions combine the only whole-genome analysis system developed at population scale with access to the largest clinical genetics reference database in the world. That gives our partners the ability to solve more cases more efficiently, to store, analyze, visualize and collaborate using all their data - at base-by-base resolution, in real time, from any browser. NextCODE is a private company headquartered in Cambridge, Massachusetts. Visit us on the web at nextcode.com

Contact:
Edward Farmer
efarmer@nextcode.com
+1-781-775-6206

© 2014 PR Newswire
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.